{"title":"氯胺酮的耀眼前景。","authors":"Ronald S Duman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p><i>About 30 percent of all people suffering from depression do not respond adequately to available treatments. Our author, a leading researcher in the field of antidepressants, says that the rediscovery of a promising, yet problematic, drug called ketamine is the most significant breakthrough for treating depression in half a century. Will ketamine inspire the next generation of antidepressants</i>?</p>","PeriodicalId":72553,"journal":{"name":"Cerebrum : the Dana forum on brain science","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353120/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Dazzling Promise of Ketamine.\",\"authors\":\"Ronald S Duman\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>About 30 percent of all people suffering from depression do not respond adequately to available treatments. Our author, a leading researcher in the field of antidepressants, says that the rediscovery of a promising, yet problematic, drug called ketamine is the most significant breakthrough for treating depression in half a century. Will ketamine inspire the next generation of antidepressants</i>?</p>\",\"PeriodicalId\":72553,\"journal\":{\"name\":\"Cerebrum : the Dana forum on brain science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353120/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cerebrum : the Dana forum on brain science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cerebrum : the Dana forum on brain science","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
About 30 percent of all people suffering from depression do not respond adequately to available treatments. Our author, a leading researcher in the field of antidepressants, says that the rediscovery of a promising, yet problematic, drug called ketamine is the most significant breakthrough for treating depression in half a century. Will ketamine inspire the next generation of antidepressants?
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
